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Aging and cancer are highly related biological phenomena.
Cellular processes that underpin several malignant pheno-
typic traits, including DNA damage responses, oxidative
stress, metabolic rewiring, and cellular senescence, also con-
tribute to aging. Reactive oxygen species (ROS) play an
essential role as intra- and extracellular messengers, orches-
trating functional and metabolic states of the cell through
the regulation of different signaling pathways [1, 2]. Impor-
tantly, ROS levels are persistently elevated in cancer cells as
a result of their increased metabolic activity, mitochondrial
dysfunction, and activation of oncogenes [3]. However,
ROS are also powerful oxidizing agents, which can induce
cell injury upon modification of lipids, proteins, or DNA,
altering normal cell physiology and increasing the risk of
DNA mutation and tumorigenesis. Autophagy is a key node
for the regulation of ROS levels as well as for ROS-dependent
cellular regulation. Autophagy comprises salvaging pro-
cesses, commonly triggered by metabolic stress responses
by which macromolecules and organelles are targeted by
autophagic vesicles to lysosomes for degradation and recy-
cling of their constituents [4]. Many studies revealed that
alterations in ROS and autophagy are implicated in cancer
biology and aging. However, while it is established that high
levels of ROS and impaired autophagy drive aging in mam-
malian cells, their role in regulating cancer cell death or sur-
vival is highly contextual and dependent on the source of
stress, tumor particularities, and its metabolic status [5].
Despite the fact that both ROS and autophagy can promote
tumorigenesis and tumor progression, their exacerbation
may induce cell death following a nonspecific injury or an
excessive degradation of macromolecules and cellular organ-
elles required for cellular processes. Interestingly, many
oncogenic stimuli that induce ROS generation also trigger
autophagy, including nutrient starvation, mitochondrial dys-
function, and hypoxia, suggesting the existence of the inter-
play between ROS and autophagy. Among the plethora of
signaling pathways regulating this interplay, the mechanistic
Target Of Rapamycin Complex 1 (mTORC1) and 5′AMP-
activated protein kinase (AMPK) interpret multiple cues,
including oxidative stress, to integrate them with the control
of energy management, anabolism, and cell growth [6]. Con-
versely, these signaling systems regulate metabolism and
growth which are in turn the major ROS sources themselves.
Thus, the understanding of the molecular mechanisms
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linking ROS and autophagy may acquire an exceptional
significance to develop novel, tailored, preventive, and thera-
peutic strategies against cancer disease and aging processes.
In this special issue, we present seven research commu-
nications dedicated to the molecular mechanisms mediated
by the crosstalk between ROS and autophagy involved in
cancer development and progression and four review
articles covering/providing a perspective of the state of the
art on some of the current developments in this emerging
field.
Melanoma is the most aggressive cancer with high mor-
tality rate, especially when diagnosed late. Intriguingly, a
number of studies support a key role of autophagy-related
genes (ARGs) in melanoma onset. D. D’Arcangelo et al.
demonstrated for the first time the expression levels of a large
number of ARGs in several melanoma samples and identified
three genes (BAG1, PEX3, and WIPI1) known to play a key
role in autophagy, as novel relevant melanoma markers.
Therefore, such molecules may represent valuable novel
markers of melanoma onset and progression.
Different studies highlight the beneficial effects of exoge-
nous preparations, such as plant-derived extracts to prevent
cancer and aging through the regulation of the interplay
between ROS and autophagy. Here, B. I. Fernandez-Gil
et al. report novel molecular insights by which melatonin
enhances the antitumor effects of irradiation and cisplatin
on head and neck squamous cell carcinoma (HNSCC) cell
lines. The authors show that melatonin induces intracellular
ROS, whose accumulation plays a role in mitochondrion-
mediated apoptosis and autophagy though upstream modula-
tion. These findings indicate that melatonin, when combined
with cisplatin and radiotherapy, is a potential adjuvant agent.
In another study by Y. Lin et al., cucurbitacin B has been
identified as a compound with antiaging activity in yeast
Saccharomyces cerevisiae through regulating autophagy,
ROS, antioxidant ability, and aging-related genes.
Resistance to tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) in cancer cells is a huge obstacle
to creating effective TRAIL-targeted clinical therapies. A
study by L. Hu et al. shows that SNX-2112, an Hsp90
inhibitor, when combined with TRAIL treatment synergis-
tically enhanced TRAIL-induced cytotoxicity in HeLa cells.
They found that SNX-2112 downregulated antiapoptotic
proteins, inhibited AKT/mTOR signaling, and induced
autophagic cell death upon the activation of a ROS/JNK/p53
signaling axis. The findings reported by the authors may pro-
vide a novel strategy to overcome apoptosis resistance during
cancer treatment.
Contrast-induced nephropathy (CIN) is a leading cause
of hospital-acquired acute kidney injury (AKI), but its phys-
iopathology and therapeutic targets remain poorly character-
ized. X. Gong et al. now report that this morbid condition
courses with the impairment of mitochondria quality control
and induction of CCL2/CCR2-mediated inflammation,
pointing towards novel mechanisms by which tetramethyl-
pyrazine (TMP) prevents CM-induced kidney injury.
M. Cordani et al. summarize the current knowledge on
sestrins (SESNs), a family of stress surveillance proteins
which play a key role in the integration of ROS control and
autophagy regulation in cancer- and age-related disorders
and may constitute an interesting source of novel therapeutic
opportunities. Hepatocellular carcinoma (HCC) is an aggres-
sive tumor with a very poor prognosis for which several envi-
ronmental risk factors, particularly viral infections and
alcohol abuse, have been shown to promote carcinogenesis
via augmentation of oxidative stress and autophagy. F.
Ciccarone et al. review in depth our current understanding
of the interplay between ROS and autophagy in HCC and
their links to risk factors, environmental stress conditions,
and therapeutic treatments.
Mitophagy is an essential cellular process that involves
the selective degradation of dysfunctional and/or damaged
mitochondria by autophagy and is requested for mitochon-
drion turnover and for responding to novel energetic
requirements. In another review article, E. Vernucci et al.
discuss the dual role that mitophagy plays in cancer- and
age-related pathologies, as a consequence of oxidative stress,
focusing on mechanisms and molecular targets for its thera-
peutic control using nanoparticles. Poly(ADP-ribosyl)ation
(PARylation) is a covalent and reversible posttranslational
modification (PTM) of proteins mediated by poly(ADP-
ribose) polymerases (PARPs) with functions in DNA repair,
replication, genome integrity, cell cycle, and metabolism.
J. M. Rodriguez-Vargas et al. review the current understand-
ing of PARP1 activation and PARylation in response to
starvation-induced autophagy.
Some DNA damage sensors, such as FOXO3a, ATM,
ATR, and p53, are important autophagy regulators, and
autophagy seems therefore to have a role in DNA damage
response (DDR). The existence of a link between autophagy
and DDR is corroborated by the evidence that alterations
in autophagy lead to increased DNA damage, highlighting
its fundamental role in the maintenance of genomic stability.
In this regard, S. Galati et al. provide novel insights about the
role of autophagy in cell response to genotoxic stress. They
report that the modulation of autophagy is a successful
approach to reduce toxicity or to enhance the activity of
anticancer drugs.
Epithelial mesenchymal transition (EMT) is considered a
driving force in tumor progression, and increasing evidence
reveals that ROS are crucial players in EMT engagement. In
this sense, Y. Sun et al. report that activating ferritinophagic
flux, by a novel iron chelator, leads the enhancement in
ROS production, highlighting its relevance as a driving force
in EMT fate.
In summary, the broad coverage in this special issue pro-
vides several new perspectives on the biology of ROS and
autophagy regulation with an emphasis on molecular aspects
and novel therapeutic approaches and places the interplay
between autophagy regulation and oxidative stress as a pri-
ority subject in biomedical research addressing aging and
cancer biology.
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